No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Analysts Conflicted on These Healthcare Names: Neurocrine (NBIX), Vertex Pharmaceuticals (VRTX) and Jasper Therapeutics (JSPR)
Jasper Launches AI Studio, Empowering Enterprise Marketing Teams to Build & Scale Generative AI Solutions
Jasper Therapeutics Initiated at Outperform by BMO Capital
Jasper Therapeutics Analyst Ratings
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Express News | Jasper Therapeutics Inc - Initial Data Expected in Second Half of 2025